Skip Navigation
Menu Search
The Sidney Kimmel Comprehensive Cancer Center

In This Section      

Research and Clinical Trials

Clinical trials come from the discoveries made in basic science laboratories. By taking these investigations and discoveries, researchers and scientists can create new therapies and treatments. Below are the listings of our current clinical trials. 

Localized

 Trial #

Name of Clinical Trial

Principal Investigator

Study Coordinator

 

R1216  

 

Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck

Ana Kiess

 

Amber Michalik

HPV-Associated 

 Trial #

Name of Clinical Trial

Principal Investigator

Study Coordinator

J1918  

Adjuvant Therapy for High-Risk HPV16-positive Oropharynx Cancer Patients with Durvalumab (MEDI4736) and MEDI0457 (INO-3112)

Carole Fakhry

Bhavika Patel

Recurrent or Metastatic Neoadjuvant

 Trial #

Name of Clinical Trial

Principal Investigator

Study Coordinator

J1923  

Preoperative Immune Checkpoint Inhibitor for Patients with Primary Untreated or Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (RM-SCCHN) Undergoing Surgical Resection (CA209-9H7)

Patrick FordeMichelle Thomas

Recurrent or Metastatic

 Trial #

Name of Clinical Trial

Principal Investigator

Study Coordinator

J15183  

A Phase II Trial of Reirradiation Combined with Open Label MK-3475 (Pembrolizumab) in Patients with Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Ana KiessRiley McIntryre
J15117  Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors (CheckMate 358)William SharmanJing Ye

Phase IIa

 Trial # 

Name of Clinical Trial

Principal Investigator

Study Coordinator

J1480           

My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents (Protocol Number: ML28897/PRO 02) 

Adrain MurphyKimberly White

Detailed descriptions of these trials are available at  www.clinicaltrials.gov